Caspofungin Acetate in Treating Children With Fever and Neutropenia
This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00020527
First received: July 11, 2001
Last updated: May 9, 2009
Last verified: March 2003
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation.
PURPOSE: Clinical trial to study the effectiveness of caspofungin acetate in treating children who have fever and neutropenia caused by a weakened immune system.
| Condition | Intervention |
|---|---|
|
Fever, Sweats, and Hot Flashes Infection Kidney Cancer Leukemia Lymphoma Neuroblastoma Neutropenia Sarcoma |
Drug: caspofungin acetate |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Supportive Care |
| Official Title: | A Multicenter, Open, Non-Comparative, Sequential Dose-Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Two Separate Doses of MK-0991 in Children With New Onset Fever and Neutropenia |
Resource links provided by NLM:
Genetics Home Reference related topics:
acute promyelocytic leukemia
cyclic neutropenia
neuroblastoma
MedlinePlus related topics:
Cancer
Fever
Kidney Cancer
Leukemia
Lymphoma
Neuroblastoma
Soft Tissue Sarcoma
Sweat
U.S. FDA Resources
Further study details as provided by National Cancer Institute (NCI):
| Study Start Date: | March 2001 |
OBJECTIVES:
- Determine the pharmacokinetics and serum levels of caspofungin acetate in immunocompromised children with new-onset fever and neutropenia.
- Determine the safety and tolerability of this drug in this patient population.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to age (2 to 11 vs 12 to 17).
Patients receive caspofungin acetate IV over 1 hour once daily for 4 to 28 days in the absence of the need to start standard empirical antifungal therapy, a breakthrough fungal infection, any deterioration of patient condition, or unacceptable toxicity.
Cohorts of 16 patients (8 per stratum) receive caspofungin acetate at 1 of 2 dose levels. Caspofungin acetate is escalated to dose level 2 if no more than 1 of 8 patients experiences dose-limiting toxicity at dose level 1.
Patients are followed at 14 days.
PROJECTED ACCRUAL: A total of 32-64 patients (16 per dose level (cohort), 8 per stratum) will be accrued for this study.
Eligibility| Ages Eligible for Study: | 2 Years to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Immunocompromised with one or more of the following conditions:
- Leukemia, lymphoma, or other cancer
- Underwent bone marrow or peripheral blood stem cell transplantation
- Aplastic anemia
- Planned chemotherapy likely to incur more than 10 days of neutropenia
- Absolute neutrophil count no greater than 500/mm^3 AND at least 1 recorded fever over 38.0 ° C within 24 hours of study
No proven invasive fungal infection at time of study entry
- Superficial fungal infection (e.g., cutaneous fungal infection, thrush, or candidal vaginitis) treatable with topical antifungals allowed
PATIENT CHARACTERISTICS:
Age:
- 2 to 17
Performance status:
- Not specified
Life expectancy:
- At least 5 days
Hematopoietic:
- See Disease Characteristics
- Hemodynamically stable with no hemodynamic compromise
Hepatic:
- AST or ALT no greater than 3 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 5 times ULN (unless related to bony metastases or other suspected bony processes)
- INR no greater than 1.6 (4.0 if receiving anticoagulants)
- No acute hepatitis or cirrhosis
Renal:
- Not specified
Other:
- Functioning central venous catheter in place
- No other condition or concurrent illness that would preclude study
- No prior allergy, hypersensitivity, or serious reaction to echinocandin antifungals
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception other than or in addition to oral contraceptives
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
Chemotherapy:
- See Disease Characteristics
Endocrine therapy:
- Not specified
Radiotherapy:
- Not specified
Surgery:
- Not specified
Other:
- No prior enrollment into this study
- No more than 48 hours since prior parenteral systemic antibacterial therapy for fever and neutropenia
- At least 14 days since prior investigational antibiotic or antifungal drugs
- Concurrent topical antifungals (i.e., nystatin and/or azole formulations) for a superficial fungal infection allowed
- No other concurrent investigational drugs, including antibiotics or antifungals
- No concurrent rifampin, cyclosporine, phenytoin, carbamazapine, phenobarbital, or other antifungal treatments (except fluconazole)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00020527
Locations
| United States, District of Columbia | |
| Children's National Medical Center | |
| Washington, District of Columbia, United States, 20010-2970 | |
| Lombardi Cancer Center | |
| Washington, District of Columbia, United States, 20007 | |
| United States, Maryland | |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Baltimore, Maryland, United States, 21231-2410 | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support | |
| Bethesda, Maryland, United States, 20892-1182 | |
| United States, Tennessee | |
| St. Jude Children's Research Hospital | |
| Memphis, Tennessee, United States, 38105-2794 | |
Sponsors and Collaborators
Investigators
| Study Chair: | Thomas J. Walsh, MD | National Cancer Institute (NCI) |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00020527 History of Changes |
| Obsolete Identifiers: | NCT00011219 |
| Other Study ID Numbers: | CDR0000068564, NCI-01-C-0084C |
| Study First Received: | July 11, 2001 |
| Last Updated: | May 9, 2009 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
recurrent childhood acute lymphoblastic leukemia recurrent childhood rhabdomyosarcoma disseminated neuroblastoma recurrent neuroblastoma recurrent Wilms tumor and other childhood kidney tumors recurrent childhood lymphoblastic lymphoma recurrent childhood acute myeloid leukemia fever, sweats, and hot flashes |
childhood acute promyelocytic leukemia (M3) recurrent/refractory childhood Hodgkin lymphoma neutropenia infection recurrent childhood small noncleaved cell lymphoma recurrent childhood large cell lymphoma previously treated childhood rhabdomyosarcoma |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Fever Leukemia Lymphoma Neuroblastoma Neutropenia Hot Flashes Sarcoma Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Body Temperature Changes Signs and Symptoms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neuroectodermal Tumors, Primitive, Peripheral Neuroectodermal Tumors, Primitive Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
ClinicalTrials.gov processed this record on May 16, 2013